Ornithine Transcarbamylase Deficiency Treatment Market

Ornithine transcarbamylase (OTC) deficiency is a genetic disorder arising due to inadequate levels of OTC, an enzyme that helps decompose and eliminate unwanted nitrogen from the human body. This process is also known as the urea cycle. Deficiency of this enzyme causes excessive nitrogen accumulation, or hyperammonemia, in the blood. Another perilous effect of this genetic disorder is the secretion of elevated levels of ammonia, which is a notorious neurotoxin. Once it reaches the central nervous system, it induces symptoms such as anorexia and overall lethargy.

Ornithine Transcarbamylase Deficiency Treatment Market contains market size and forecasts of Ornithine Transcarbamylase Deficiency Treatment in Global, including the following market information:

Global Ornithine Transcarbamylase Deficiency Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Ornithine Transcarbamylase Deficiency Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Oral Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Ornithine Transcarbamylase Deficiency Treatment include Abbott Laboratories, Nutricia (Danone Group), Mead Johnson (Reckitt Benckiser), Horizon Therapeutics, Nestle, Bausch Health Companies, Ultragenyx Pharmaceutical, Arcturus Therapeutics and Acer Therapeutics. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Ornithine Transcarbamylase Deficiency Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Ornithine Transcarbamylase Deficiency Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Ornithine Transcarbamylase Deficiency Treatment Market Segment Percentages, by Type, 2021 (%)

Oral

Intravenous

Global Ornithine Transcarbamylase Deficiency Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Ornithine Transcarbamylase Deficiency Treatment Market Segment Percentages, by Application, 2021 (%)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Global Ornithine Transcarbamylase Deficiency Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Ornithine Transcarbamylase Deficiency Treatment Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Ornithine Transcarbamylase Deficiency Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Ornithine Transcarbamylase Deficiency Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Abbott Laboratories

Nutricia (Danone Group)

Mead Johnson (Reckitt Benckiser)

Horizon Therapeutics

Nestle

Bausch Health Companies

Ultragenyx Pharmaceutical

Arcturus Therapeutics

Acer Therapeutics